Organogenesis is a leading regenerative medicine company focused on empowering healing through the development, manufacturing and sale of products for the advanced wound care, surgical and sports medicine markets. Our mission is to provide an integrated portfolio of healing solutions that improve lives while lowering the overall cost of health care. We are relentless in the pursuit of quality and innovations that make all the difference.
Apligraf® is a living cell-based product, developed by Organogenesis and indicated for the treatment of venous leg ulcers and diabetic foot ulcers. Apligraf is:
Dermagraft is FDA approved for treating diabetic foot ulcers – a vital part of the Organogenesis suite of products specializing in bioactive wound healing and soft tissue regeneration.
The first purified collagen matrix plus PHMB antimicrobial.
Our product portfolio offers a complete line of state-of-the-art products that take advantage of the unique healing properties of amniotic tissues and fluids. These products are recognized for their excellent regenerative, anti-inflammatory, anti-scarring, and angiogenic properties.
NuTech Medical’s portfolio includes an amniotic product line for both soft tissue and bone applications, utilized in multiple markets including wound healing and surgery. The product line includes Affinity®, an innovative, fresh amniotic allograft; NuShield®, a dehydrated terminally-sterilized allograft that comprises both the amnion and chorion layers; and NuCel® and ReNu®, cryopreserved allografts derived from human amnion and amniotic fluid, as well as other complementary products.
NuTech’s proprietary BioLoc™ process is the field’s state-of-the-art technology for preserving the native structure of the amnion and chorion membranes, optimized to provide excellent strength, flexibility, and handling. NuTech’s proprietary AlloFresh™ process allows for the fresh hypothermic storage of amniotic tissues while retaining their structural integrity, viability, and native benefits.